Arca
Skip to content
Tools
Tools

Mercaptopurine Tablets

Recall D-0367-2024, part of FDA recall event 93960. See Stason Pharmaceuticals's company page.

Stason Pharmaceuticals, Inc. started this Class III drug recall on Feb 9, 2024 (voluntary: firm initiated); FDA lists it as terminated, terminated Feb 5, 2026.

  • Classification: Class III
  • Started: Feb 9, 2024
  • Status: Terminated

Why It Was Recalled

Class III

Failed Dissolution Specifications: results slightly under spec at at 9-months.

Record

Product
Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC 69076-913-25), Rx only, Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL, www.quinnrx.com
Quantity
54, 131 bottles
Lots and codes
Lot #: a)22K012, 22K013A, Exp: 04/30/2024; 23A001, 23A002A, Exp: 07/31/2024; 23D006, 23D007A, 23D007C, Exp:10/31/2024; b)22K013B, Exp: 04/30/2024; 23A002B, Exp:07/31/2024; 23D007B, Exp: 10/31/2024.
Distribution
USA Nationwide
Recalling firm
Stason Pharmaceuticals, Inc., Irvine, CA, United States
How the firm notified
Letter
FDA classified
Mar 6, 2024

Stason Pharmaceuticals, Inc.'s Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.